Botensilimab

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium. The conference will take place on January 23-25, 2025, in San Francisco, California. The presentations will showcase BOT/BAL's activity across three distinct colorectal cancer settings—late-line metastatic, first-line, and neoadjuvant treatment. The studies demonstrate BOT/BAL’s consistent activity in microsatellite stable (MSS) colorectal cancer (CRC), which accounts for over 80% of CRC cases and has limited treatment options, as well as its efficacy in microsatellite instability-high (MSI-H) CRC. Additionally, one presentation will feature BOT/BAL and invariant natural killer T cells (iNKTs) in patients with refractory gastric cancer. “These presentations will highlight BOT/BAL’s potential to benefit patients across colorectal cancer treatment settings, including the neoadjuvant, late-line, and first-line settings,” said Dr. Garo Armen, Chairman and CEO of Agenus. “We aim to transform outcomes at every stage of disease and deliver renewed hope for patients worldwide.” Presentation Details Abstract Title: Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM)* Abstract Number: 23 Presenting Author: Dr. Marwan Fakih Session: Rapid Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus Session Date and Time: 1/25/2025, 9:15 AM-10:00 AM PST Abstract Title: Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO Abstract Number: 158 Presenting Author: Dr. Filippo Ghelardi Session: Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date and Time: 1/25/2025, 7:00 AM-7:55 AM PST Abstract Title: A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma Abstract Number: TPS515 Presenting Author: Dr. Samuel Cytryn Session: Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers Session Date and Time: 1/23/2025, 11:30 AM-1:00 PM PST Abstract Title: Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update Abstract Number: 207 Presenting Author: Dr. Erika Hissong Session: Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date and Time: 1/25/2025, 7:00 AM-7:55 AM PST Abstract Title: A phase 1 trial of folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) in microsatellite stable metastatic colorectal cancer. Abstract Number: 180 Presenting Author: Dr. Marwan Fakih Session: Poster Session C: Cancers of the Colon, Rectum, and Anus Session Date and Time: 1/25/2025, 7:00 AM-7:55 AM PST Complete abstracts will be released at 5:00 PM ET on January 21 st , 2025. Data presented at the conference will be available to view in the publications section of the Agenus website ( https://agenusbio.com/publications ) following the ASCO GI Meeting. *Agenus Sponsored Study About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Plus, news about Foghorn Therapeutics, Incyte, BioNTech, Galderma, Basilea, Innovia, Pharming, bit.bio, Promise Bio, Outlook Therapeutics and Trevi Therapeutics: Candid Therapeutics’ trio of T cell engager deals: The company is paying up to $320 million in upfront and milestones to Nona Biosciences to develop next-generation T cell engagers. It’s also partnering with Ab Studio to discover T cell engagers that treat autoimmune diseases. No terms were disclosed. And, in its third announcement, Candid also said Monday that it will spend up to $1 billion in a deal with EpimAb Biotherapeutics that also aims to develop T cell engagers in the autoimmune category. — Jaimy Lee PepGen’s Duchenne trial put on hold: The biotech said the FDA put its CONNECT2-EDO51 study on hold. It’s a Phase 2 trial assessing multiple ascending doses in patients with Duchenne muscular dystrophy. Its stock $PEPG sank 28% on Monday morning. — Jaimy Lee Foghorn to drop AML candidate: The company is stopping work on an experimental drug for acute myeloid leukemia called FHD-286, and it’s seeking a potential partner for the drug. Foghorn said that it saw responses to the drug in a Phase 1 study, but “the observed response rate did not meet the company’s threshold to continue development by Foghorn alone.” — Lei Lei Wu Incyte stops developing anemia drug for patients with myelofibrosis: During an investor day last week, the company said zilurgisertib “does not significantly improve anemia in patients with myelofibrosis,” and it had halted work on the drug. — Katherine Lewin BioNTech, OncoC4’s partial clinical hold is lifted: The FDA gave the go-ahead to the partners to continue a Phase 3 lung cancer trial of an anti-CTLA-4 antibody called gotistobart, but only in a subset of patients, BioNTech disclosed Friday. In October, the study was put on partial clinical hold due to a “a possible variance in results between the squamous and non-squamous NSCLC patient populations.” The study will now only enroll squamous NSCLC patients. — Lei Lei Wu FDA approves Galderma’s Nemluvio in moderate-to-severe atopic dermatitis: The drug is now approved to treat patients 12 years and older. Nemluvio is also approved for prurigo nodularis, another chronic skin condition. According to Galderma, Nemluvio is the first approved monoclonal antibody that specifically targets the cytokine IL-31, which causes the itching and inflammation associated with the disease. Its Swiss-listed shares $GALD were up about 7% on Monday. — Katherine Lewin Basilea inks deal with Innoviva to market antibiotic: Innoviva is paying Basilea $4 million upfront and up to $223 million in sales milestones, plus royalties, to commercialize Zevtera in the US. The anti-MRSA antibiotic received FDA approval in April. — Jaimy Lee Pharming’s $66M offer to buy Abliva: Pharming wants to buy the Swedish company, which is developing a treatment for mitochondrial disease. The lead asset is currently in a pivotal trial. — Jaimy Lee Bit.bio raises $30M for cell therapy pipeline: The biotech plans to use the proceeds to invest in new tools for drug discovery and research. The fundraise was led by M&G Investments, with support from backers including ARCH Venture Partners and Milky Way. The company unveiled its lead program , which is designed to regenerate the liver, a year ago. — Ayisha Sharma Israeli biotech secures $8.3M in seed funding: Promise Bio expects to use the cash to develop a computational platform powered by AI and epiproteomics that could help predict patient responses to treatment. The round was led by Awz Ventures. AION Labs also invested. — Ayisha Sharma Outlook to cut 23% of its workforce: The company underwent a strategic review as it aims to shore up funds to support the launch of its new wet AMD treatment, which was approved in Europe and the UK this year. The company plans to submit its formulation of bevacizumab to the FDA in the first three months of next year after receiving a complete response letter last year. Outlook had 24 full-time employees, as of September 2023.— Jaimy Lee Trevi is selling 12.5 million shares at $4.00 apiece to raise $50 million. — Jaimy Lee